Tekla Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tekla Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$18.3M	Sell	210,789 -89,300	-30%	-$8.4M	0.72%	40
2023 Q1	$29.2M	Buy	300,089 +69,299	+30%	+$7.18M	1.11%	24
2022 Q4	$23.9M	Buy	230,790 +79,843	+53%	+$7.5M	0.9%	36
2022 Q3	$12.8M	Buy	150,947 +22,943	+18%	+$2.04M	0.52%	47
2022 Q2	$10.6M	Hold	128,004	–	–	0.42%	57
2022 Q1	$9.87M	Hold	128,004	–	–	0.35%	62
2021 Q4	$11.3M	Hold	128,004	–	–	0.36%	62
2021 Q3	$9.89M	Hold	128,004	–	–	0.32%	74
2021 Q2	$10.7M	Hold	128,004	–	–	0.35%	79
2021 Q1	$9.67M	Sell	128,004 -150,326	-54%	-$12.3M	0.33%	76
2020 Q4	$24.4M	Sell	278,330 -47,492	-15%	-$3.77M	0.86%	34
2020 Q3	$24.8M	Buy	325,822 +80,460	+33%	+$8.14M	0.93%	29
2020 Q2	$30.3M	Sell	245,362 -25,251	-9%	-$2.51M	1.15%	22
2020 Q1	$22.9M	Sell	270,613 -5,947	-2%	-$512K	1.03%	23
2019 Q4	$23.4M	Buy	276,560 +30,797	+13%	+$2.33M	0.88%	29
2019 Q3	$16.6M	Hold	245,763	–	–	0.72%	34
2019 Q2	$21.1M	Buy	245,763 +23,677	+11%	+$2.03M	0.86%	30
2019 Q1	$19.7M	Buy	222,086 +14,652	+7%	+$1.36M	0.8%	30
2018 Q4	$17.7M	Buy	207,434 +66,896	+48%	+$6.36M	0.76%	33
2018 Q3	$13.6M	Hold	140,538	–	–	0.49%	48
2018 Q2	$13.2M	Sell	140,538 -140,538	-50%	-$12.3M	0.5%	45
2018 Q1	$22.8M	Sell	281,076 -208,669	-43%	-$17.9M	0.89%	29
2017 Q4	$43.7M	Sell	489,745 -12,000	-2%	-$1.04M	1.68%	15
2017 Q3	$46.7M	Hold	501,745	–	–	1.67%	16
2017 Q2	$45.6M	Sell	501,745 -4,100	-0.8%	-$373K	1.69%	17
2017 Q1	$44.4M	Sell	505,845 -66,800	-12%	-$5.94M	1.72%	18
2016 Q4	$47.4M	Sell	572,645 -137,500	-19%	-$11.8M	2.02%	12
2016 Q3	$65.7M	Buy	710,145 +56,300	+9%	+$5.3M	2.53%	9
2016 Q2	$50.9M	Buy	653,845 +57,700	+10%	+$4.91M	2.08%	12
2016 Q1	$49.2M	Hold	596,145	–	–	2.09%	12
2015 Q4	$62.5M	Buy	596,145 +25,668	+4%	+$2.68M	2.26%	12
2015 Q3	$60.1M	Buy	570,477 +35,500	+7%	+$4.74M	2.16%	13
2015 Q2	$73.2M	Hold	534,977	–	–	2.65%	13
2015 Q1	$66.7M	Sell	534,977 -35,050	-6%	-$3.71M	2.64%	8
2014 Q4	$51.5M	Sell	570,027 -140,500	-20%	-$11.7M	2.41%	12
2014 Q3	$51.3M	Buy	710,527 +289,143	+69%	+$19M	2.4%	11
2014 Q2	$26.2M	Hold	421,384	–	–	2.41%	13
2014 Q1	$28.7M	Buy	421,384 +163,143	+63%	+$12M	2.87%	11
2013 Q4	$18.1M	Buy	258,241 +76,371	+42%	+$5.19M	1.91%	17
2013 Q3	$13.1M	Buy	181,870 +106,870	+142%	+$7.1M	1.46%	23
2013 Q2	$4.18M	Buy	+75,000	New	+$4.67M	0.57%	43

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tekla Capital Management's BMRN Position: Q2 2023 in Review

Tekla Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 30% in Q2 2023, selling an estimated $8.4M and leaving 210,789 shares worth $18.3M. The position accounts for 0.72% of the portfolio, ranked #40.

Tekla Capital Management first reported a position in BMRN in Q2 2013 and has held it in 41 quarters since. The position peaked at $73.2M in Q2 2015. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Tekla Capital Management held 210,789 shares of BioMarin Pharmaceuticals worth $18.3M as of Q2 2023.
Tekla Capital Management sold 89,300 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $8.4M.
BioMarin Pharmaceuticals made up 0.72% of Tekla Capital Management's portfolio in Q2 2023, its #40 holding.
Tekla Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
Tekla Capital Management's BioMarin Pharmaceuticals position peaked at $73.2M in Q2 2015.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.